Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

J Clin Pharmacol. 1994 Feb;34(2):111-9. doi: 10.1002/j.1552-4604.1994.tb03974.x.

Authors

C C Peck¹, W H Barr, L Z Benet, J Collins, R E Desjardins, D E Furst, J G Harter, G Levy, T Ludden, J H Rodman, et al.

Affiliation

¹ Center for Drug Evaluation and Research, FDA, Rockville, Maryland 20857.

PMID: 8163710
DOI: 10.1002/j.1552-4604.1994.tb03974.x

No abstract available

MeSH terms

Animals
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Approval*
Drug Evaluation, Preclinical
Drug Labeling
Drugs, Investigational* / pharmacokinetics
Drugs, Investigational* / pharmacology
Drugs, Investigational* / toxicity
Humans

Substances

Drugs, Investigational